SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Artelo Biosciences to Showcase ART26.12 Pain Treatment at IASP Congress

Artelo Biosciences will present its first-in-human FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain. The presentation will introduce ART26.12 as the first selective FABP5 inhibitor to enter human clinical st

ARTL

Related stories